Export financials
PolyPid Ltd. (PYPD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

PolyPid Ltd. Financial Statements 2025-2011 | PYPD
Annual Financial Statements PolyPid Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
67.7 M | 18.7 M | 7.65 M | 227 K | 2.52 M | 107 M | 2.25 M | 196 K | - | - | - | - | - | - | - |
Shares |
16.4 M | 5.91 M | 1.4 M | 648 K | 624 K | 9.58 M | 562 K | 561 K | - | - | - | - | - | - | - |
Historical Prices |
4.14 | 3.16 | 5.45 | 0.35 | 4.04 | 11.2 | - | - | - | - | - | - | - | - | - |
Net Income |
-34.2 M | -29 M | -23.9 M | -39.6 M | -42.6 M | -36.9 M | -6.9 M | 5.92 M | -54.5 M | -11.4 M | -9.75 M | - | -3.88 M | -1.79 M | - |
Operating Income |
-33 M | -28 M | -22.9 M | -38.9 M | -43.1 M | -26.3 M | -18.6 M | -18.4 M | - | - | - | - | - | - | - |
EBITDA |
-31.5 M | -26.4 M | -21 M | -37.2 M | -42 M | -25.3 M | -17.6 M | -18 M | -13.6 M | -10.1 M | -8.46 M | - | -3.51 M | -1.73 M | - |
Operating Expenses |
- | - | - | - | - | - | 18.6 M | 18.4 M | 13.8 M | 10.3 M | 8.57 M | - | 3.58 M | 1.79 M | - |
General and Administrative Expenses |
7.18 M | 4.27 M | 5.52 M | 8.01 M | 9.61 M | 7.7 M | 4.48 M | 5.81 M | 4.06 M | 2.55 M | 2.93 M | - | 938 K | 410 K | - |
All numbers in USD currency
Quarterly Income Statement PolyPid Ltd.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
16.4 M | 12.8 M | 5.91 M | 5.02 M | 1.4 M | 44.4 M | - | - | - | - | 18.8 M | - | 18.8 M | - | 18.5 M | - | - | - | 563 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-34.2 M | -9.98 M | -29 M | -6.29 M | -23.9 M | -5.84 M | - | - | - | - | - | - | -10.5 M | - | - | - | -17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-33 M | -9.4 M | -28 M | -6.12 M | -22.9 M | -5.82 M | - | - | - | - | - | - | -10.6 M | - | - | - | -7.27 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-31.5 M | -8.65 M | -26.4 M | -5.29 M | -21 M | -4.91 M | - | - | - | - | - | - | -10.6 M | - | - | - | -7.27 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
7.18 M | 2.49 M | 4.27 M | 1.1 M | 5.52 M | 1.5 M | - | - | - | - | - | - | 2.45 M | - | - | - | 2.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Main types of financial statements PolyPid Ltd. PYPDFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting PolyPid Ltd. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Фармсинтез
LIFE
|
- | - | - | ||
|
Aclaris Therapeutics
ACRS
|
$ 5.64 | 5.92 % | $ 691 M | ||
|
Akebia Therapeutics
AKBA
|
$ 0.99 | 4.33 % | $ 255 M | ||
|
Alector
ALEC
|
$ 2.19 | 2.1 % | $ 226 M | ||
|
Aligos Therapeutics
ALGS
|
$ 5.08 | 0.96 % | $ 50.2 M | ||
|
Alkermes plc
ALKS
|
$ 45.83 | 0.22 % | $ 7.55 B | ||
|
Allogene Therapeutics
ALLO
|
$ 1.79 | 0.28 % | $ 395 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 248.37 | 0.14 % | $ 32.5 B | ||
|
Altimmune
ALT
|
$ 3.31 | 1.22 % | $ 292 M | ||
|
ALX Oncology Holdings
ALXO
|
$ 1.93 | 0.52 % | $ 104 M | ||
|
Amgen
AMGN
|
$ 380.17 | 0.75 % | $ 205 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 23.96 | 0.74 % | $ 1.12 B | ||
|
Amarin Corporation plc
AMRN
|
$ 14.02 | 1.59 % | $ 5.82 B | ||
|
Amneal Pharmaceuticals
AMRX
|
$ 17.23 | 1.29 % | $ 5.4 B | ||
|
AbbVie
ABBV
|
$ 261.94 | 1.87 % | $ 463 B | ||
|
AnaptysBio
ANAB
|
$ 54.77 | 1.67 % | $ 1.58 B | ||
|
Anika Therapeutics
ANIK
|
$ 21.22 | 1.7 % | $ 304 M | ||
|
ANI Pharmaceuticals
ANIP
|
$ 70.92 | 1.04 % | $ 1.42 B | ||
|
Aprea Therapeutics
APRE
|
$ 0.76 | 2.03 % | $ 4.97 M | ||
|
Aptevo Therapeutics
APVO
|
$ 1.87 | 2.75 % | $ 590 K | ||
|
AbCellera Biologics
ABCL
|
$ 11.04 | 1.38 % | $ 3.3 B | ||
|
Aquestive Therapeutics
AQST
|
$ 4.89 | 2.41 % | $ 523 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
$ 15.23 | 3.39 % | $ 417 M | ||
|
Ardelyx
ARDX
|
$ 3.54 | 0.14 % | $ 853 M | ||
|
Armata Pharmaceuticals
ARMP
|
$ 5.3 | 1.84 % | $ 192 M | ||
|
Arcutis Biotherapeutics
ARQT
|
$ 24.35 | 1.95 % | $ 3.1 B | ||
|
Artelo Biosciences
ARTL
|
$ 5.15 | 1.1 % | $ 974 K | ||
|
Arvinas
ARVN
|
$ 8.44 | 0.41 % | $ 598 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
$ 80.24 | 0.11 % | $ 10.7 B | ||
|
Assembly Biosciences
ASMB
|
$ 28.86 | 0.64 % | $ 324 M | ||
|
Actinium Pharmaceuticals
ATNM
|
$ 1.25 | 6.87 % | $ 39 M | ||
|
Atara Biotherapeutics
ATRA
|
$ 9.49 | 1.17 % | $ 119 M | ||
|
Agenus
AGEN
|
$ 7.12 | 2.59 % | $ 212 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | 1.26 % | $ 2.19 B | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.94 | 2.93 % | $ 516 M | ||
|
Atea Pharmaceuticals
AVIR
|
$ 5.34 | 0.47 % | $ 435 M | ||
|
Axon Enterprise
AXON
|
$ 491.2 | 2.47 % | $ 38.4 B | ||
|
Axsome Therapeutics
AXSM
|
$ 216.73 | 0.75 % | $ 10.8 B | ||
|
Aytu BioScience
AYTU
|
$ 2.0 | 0.5 % | $ 12.6 M | ||
|
BridgeBio Pharma
BBIO
|
$ 72.33 | 0.1 % | $ 13.9 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
$ 8.2 | 0.92 % | $ 1.72 B | ||
|
Bicycle Therapeutics plc
BCYC
|
$ 3.87 | 0.13 % | $ 268 M | ||
|
Black Diamond Therapeutics
BDTX
|
$ 2.03 | 2.52 % | $ 115 M | ||
|
Beam Therapeutics
BEAM
|
$ 24.35 | 1.5 % | $ 2.41 B | ||
|
Biogen
BIIB
|
$ 217.62 | 0.22 % | $ 31.9 B | ||
|
BioLineRx Ltd.
BLRX
|
$ 2.48 | 0.2 % | $ 6.11 B | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 66.22 | 0.82 % | $ 12.7 B | ||
|
Bristol-Myers Squibb Company
BMY
|
$ 64.03 | 0.61 % | $ 130 B | ||
|
Benitec Biopharma
BNTC
|
$ 12.11 | 0.08 % | $ 498 M | ||
|
Burford Capital Limited
BUR
|
$ 4.35 | 1.13 % | $ 953 M |